Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (42)

I-06

A New Protocol for the Administration of Etoposide–Cisplatin in Metastatic Small Cell Lung Cancer

Wednesday 10:20-11:40

I-09

Modelling and translating head and neck radiation therapy on all three levels: in vitro, in vivo and clinical

Wednesday 10:20-11:40

I-16María García-Cremades

A comparison of different model-based approaches to scale preclinical to clinical tumour growth inhibition in gemcitabine-treated pancreatic cancer

Wednesday 10:20-11:40

I-20Ekaterina Gibiansky

Population Pharmacokinetic of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Other Indolent Non-Hodgkin’s Lymphoma (iNHL) Subtypes, Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL)

Wednesday 10:20-11:40

I-28Sebastiaan Goulooze

Monte-Carlo simulations of sunitinib therapeutic drug monitoring in patients with gastrointestinal stromal tumours.

Wednesday 10:20-11:40

I-30Joachim Grevel

Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC)

Wednesday 10:20-11:40

I-31Monia Guidi

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Wednesday 10:20-11:40

I-37Fangran Hao

Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft

Wednesday 10:20-11:40

I-40Andrea Henrich

PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model

Wednesday 10:20-11:40

I-42Jennifer Hibma

Population Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in ALL and NHL Patients

Wednesday 10:20-11:40

I-50Diane-Charlotte Imbs

Modeling and simulation for improving the efficacy of the combination between antiangiogenic and chemotherapy in Non Small Cell Lung Cancer

Wednesday 10:20-11:40

I-59Matts Kågedal

Selection of exposure metrics AUC, Cmax or Cmin in exposure response analyses – a simulation study.

Wednesday 10:20-11:40

I-63Lena Klopp-Schulze

Tamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations

Wednesday 10:20-11:40

II-04Maurice Ahsman

Modelling and simulation of oral GnRH Antagonist TAK-385 and testosterone-lowering response in Prostate Cancer Patients to Optimize Trial Design and Dose Selection

Wednesday 15:10-16:30

II-05Sihem Bihorel

A plateform PK/PD Model for Antibody Drug Conjugates Induced Myelosuppression

Wednesday 15:10-16:30

II-27Jennifer Bonner

Building of virtual geriatric cancer populations for physiologically-based pharmacokinetic modelling and simulation in cancer patients greater than 70 years of age

Wednesday 15:10-16:30

II-36Tim Cardilin

Extending the Tumor Static Concentration curve to average doses – a combination therapy example using radiation therapy

Wednesday 15:10-16:30

II-40Pascal Chanu

A model to predict progression free survival in patients with previously untreated HER2-positive progressive or recurrent locally advanced or metastatic breast cancer based on tumor growth inhibition metrics

Wednesday 15:10-16:30

II-43Christophe Chassagnole

Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour

Wednesday 15:10-16:30

II-48

A model to predict progression-free survival in patients with renal cell carcinoma based on week 8 change in tumor size

Wednesday 15:10-16:30

II-55Damien Cronier

PK/PD Modeling of Overall and Progression-Free Survival in Advanced Soft Tissue Sarcoma Patients Treated With Olaratumab in Combination with Doxorubicin.

Wednesday 15:10-16:30

II-61Bernardo de Miguel Lillo

Modeling the dynamics of alanine aminotransferase in advanced cancer patients treated with kahalalide F

Wednesday 15:10-16:30

II-63Aurelia de Vries Schultink

Pharmacokinetics of MCLA-128 in cynomolgus monkeys and extrapolation to humans to support selection of first-in-human dose

Wednesday 15:10-16:30

II-67Laurence Del Frari

Predicting human pharmacokinetics of monoclonal antibodies by allometric translation from preclinical data: a case study

Wednesday 15:10-16:30

III-09Sreenath M Krishnan

Population modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib

Thursday 10:05-11:30

III-21Litaty Céphanoée Mbatchi

Pharmacokinetics modelling of temsirolimus and its active metabolite

Thursday 10:05-11:30

III-23Evgeny Metelkin

Development of immune responce template forsystems pharmacology modeling of immunotherapy in oncology

Thursday 10:05-11:30

III-44Zinnia Parra-Guillen

Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment

Thursday 10:05-11:30

III-47Belén Pérez Solans

Markov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients

Thursday 10:05-11:30

III-56Philippe Pierrillas

From mouse to human: comparison of interspecies translational strategies using integrative semi-mechanistic PK-PD models and PBPK-PD modeling to forecast efficacious clinical dose

Thursday 10:05-11:30

IV-05Emilie Schindler

PK-PD modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size as predictors of overall survival in axitinib-treated metastatic renal cell carcinoma (mRCC) patients

Thursday 14:40-16:00

IV-09Kevin Smart

Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab

Thursday 14:40-16:00

IV-16Oleg Stepanov

A quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions

Thursday 14:40-16:00

IV-24Rob ter Heine

The influence of erythrocyte accumulation on everolimus pharmacokinetics and pharmacodynamics in cancer patients

Thursday 14:40-16:00

IV-27Hoai-Thu Thai

Model-based drug development to support isatuximab dosing regimen selection in Phase II multiple myeloma patients

Thursday 14:40-16:00

IV-29Yingying Tian

Population pharmacokinetic analysis of everolimus in patients with solid tumors

Thursday 14:40-16:00

IV-33Elena Tosca

Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment

Thursday 14:40-16:00

IV-34Mira Tout

Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia

Thursday 14:40-16:00

IV-55Siyuan Wang

An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for sunitinib combined with dopamine in the treatment of drug-resistant breast cancer

Thursday 14:40-16:00

IV-64Jan-Georg Wojtyniak

A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome

Thursday 14:40-16:00

IV-70Huixin Yu

Development of a pharmacokinetic model for pazopanib – a tyrosine kinase inhibitor used for the treatment of solid tumours

Thursday 14:40-16:00

IV-76Li Zhu

Population Pharmacokinetic Modeling of Ulocuplumab, an anti-CXCR4 Monoclonal Antibody in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Multiple Myeloma

Thursday 14:40-16:00